A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941

D. Sarker, R. Kristeleit, K. E. Mazina, J. A. Ware, Y. Yan, M. Dresser, M. K. Derynck, J. De-Bono

Research output: Contribution to journalMeeting abstract

Original languageEnglish
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 2009

Cite this